Total creatine (Cr) levels are widely used as an internal reference for the quantification of other metabolites in 1 H magnetic resonance spectroscopy (MRS). However, Cr plays an important role in brain energy metabolism, and its levels can be modulated by conditions of energy production and demand. Therefore, abnormal Cr levels in patient vs. control populations could confound the utility of this metabolite as an internal reference. We quantified Cr levels in 22 healthy controls, 15 acutely manic patients with bipolar disorder and 15 acutely ill patients with schizophrenia using 1 H MRS in the anterior cingulate cortex, and the parieto-occipital cortex at 4 Tesla. Patients with schizophrenia had a statistically significant reduction in Cr levels as compared with controls; bipolar disorder patients showed no difference in Cr as compared with controls. In addition, older age was associated with reductions in Cr in healthy controls, but not in patients with either disorder. These findings indicate that the use of Cr as an internal reference in schizophrenia MRS research is problematic unless Cr levels are shown to be normal in the study population. They also add to the literature on bioenergetic abnormalities in schizophrenia.
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Introduction
In vivo proton magnetic resonance spectroscopy ( 1 H MRS)
investigations of the human brain reveal a prominent singlet at 3.03 ppm arising from a combination of creatine and phosphocreatine (termed total creatine, we will abbreviate Cr). Cr concentration in the human brain varies between 6 and 10 mM, although it is reported to be at the higher end of this range in grey matter (Govindaraju et al., 2000) . Phosphocreatine acts as a reservoir for the generation of ATP in neurons; although Cr levels are typically maintained within a narrow range, short periods of intense energy requirement can lead to rapid breakdown of phosphocreatine and possibly reduce overall Cr levels (Kato et al., 1996) . Thus Cr may act as a marker of cellular energy production. The magnitude of the Cr peak has been widely used as a concentration reference in human MRS studies, where measures of other metabolites are reported as ratios to Cr. This reduces subjectspecific sources of variance inherent in 1 H MRS data and is valid if Cr levels do not change systematically across study groups. Despite the widespread use of this approach in studies of neuropsychiatric conditions, few studies have explicitly examined this assumption. Several recent studies have found reduced Cr levels in the dorsolateral prefrontal cortex in bipolar disorder (Frey et al., 2007) , the anterior cingulate cortex in schizophrenia (Theberge et al., 2007) , and dorsolateral prefrontal cortex of individuals at high risk of psychosis (Wood et al., 2003) , but elevated Cr levels in the prefrontal cortex in major depressive disorder (Gruber et al., 2003) . Cr levels have also been variably reported to increase (Saunders et al., 1999) or decrease (Charles et al., 1994) with advancing age. In this report, we examine Cr levels in acutely ill, medicated, bipolar disorder and schizophrenia patients using 1 H MRS at 4 Tesla. We hypothesized based on the previous literature that we would find reductions in Cr levels in both patient groups. To test the regional specificity of our findings, we report data from two brain regions: the anterior cingulate cortex (ACC) which is implicated in psychiatric disorders (Öngür and Price, 2000) and the parieto-occipital cortex (POC) as a control region.
Methods

Subjects
Following approval by the McLean Hospital IRB, data were obtained from 22 healthy control (NC), 15 bipolar manic (BD) and 15 schizophrenia (SZ) subjects (7 SZ subjects diagnosed with schizoaffective disorder). An additional 24 BD and 3 SZ subjects were recruited for the study but were not able to provide usable data. Inability to tolerate the scanning environment due to psychiatric condition was the primary reason for drop-out. BD subjects who did not complete the study were somewhat more symptomatic (YMRS:26.9; MADRS:18.4; PANSS:82.0) than those who did (see Table 1 ). All patients were hospitalized with acute episodes. Patients were assessed using the structured clinical interview for the DSM-IV, as well as the Positive and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), and the Montgomery-Asberg Depression 
